• Evotec outlined a strategy built on faster-than-market growth, a shift toward higher-value segments, and tighter operational execution.
• Cost-out plan targets more than EUR 60 million impact in FY 2025, including about 600 D&PD FTE reductions; additional measures lifted to EUR 30 million.
• Asset-lighter pivot highlighted by an agreed sale of the Toulouse Just Evotec Biologics site to Sandoz, paired with a technology license.
• Deal terms include about USD 350 million upfront in 2025, more than USD 300 million in transition-period license, milestone and development revenue in 2026-2028.
• Royalty stream tied to 10 biosimilars from first commercial sales beyond 2028; milestone and royalty potential flagged at more than EUR 500 million to 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.